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Abstract
Introduction: Cecal ligation and puncture (CLP) is an inflammatory condition that leads to multisystemic organ
failure. Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro
to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear
factor (NF)-B activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression. The aim of this
study was to evaluate the effects of flavocoxid in a murine model of CLP-induced polymicrobial sepsis.
Methods: C57BL/6J mice were subjected to CLP or sham operation. In a first set of experiments, an intraperitoneal
injection of flavocoxid (20 mg/kg) or vehicle was administered 1 hour after surgery and repeated every 12 hours.
Survival rate was monitored every 24 hours throughout 120 hours. Furthermore, additional groups of sham and
CLP mice were killed 18 hours after surgical procedures for blood-sample collection and the lung and liver were
collected for biomolecular, biochemical and histopathologic studies.
Results: COX-2, 5-LOX, tumor necrosis factor-a (TNF-a), interleukin (IL)-6, IL-10, extracellular-regulated-kinase 1/2
(ERK), JunN-terminal kinase (JNK), NF-B, and b-arrestin 2 protein expression were evaluated in lung and liver with
Western blot analysis. In addition, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), cytokines, and lipoxin A4 serum
content were measured with an enzyme-linked immunosorbent assay (ELISA). Flavocoxid administration improved
survival, reduced the expression of NF-B, COX-2, 5-LOX, TNF-a and IL-6 and increased IL-10 production. Moreover,
flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved b-arrestin 2 expression,
reduced blood LTB4, PGE2, TNF-a and IL-6, and increased IL-10 and lipoxin A4 serum levels. The treatment with
flavocoxid also protected against the histologic damage induced by CLP and reduced the myeloperoxidase (MPO)
activity in the lung and liver.
Conclusions: Flavocoxid protects mice from sepsis, suggesting that this dual inhibitor may represent a promising
approach in such a life-threatening condition.
Introduction
Cecal ligation and puncture (CLP) is an experimental
model of shock that reproduces all the pathologic seque-
lae of sepsis that occur in intensive care patients [1].
Despite a massive effort invested in developing potential
therapies, to date, severe sepsis is still a common,
frequently fatal, and expensive pathologic condition [2].
Sepsis is a systemic inflammatory response to infection
triggered by Gram-positive and/or -negative organisms,
which can proliferate and/or release endotoxin and exo-
toxins that stimulate monocytes, macrophages, endothe-
lial cells, and neutrophils to an overproduction and
release of major inflammatory mediators, followed by tis-
sue injury which in turn, culminates in multiple-system
organ failure (MOF). The first step of this signaling path-
way involves Toll-like receptors (TLRs) binding to the
bacterial cell-wall components, which induces nuclear
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factor (NF)-B/IB system activation that exerts tran-
scriptional regulation on proinflammatory genes and
encodes various adhesion molecules, cytokines, and other
proinflammatory mediators. In addition, TLRs activate
MAP kinases, including extracellular-regulated-kinase 1/
2 (ERK), JunN-terminal kinase (JNK), and p38 [3,4].
Recently, it was demonstrated that b-arrestins, adaptor
proteins involved in G protein-coupled receptor (GPCR)
desensitization, are also implicated in regulation of TLR
signaling and proinflammatory gene expression. Further-
more, it has been suggested that b-arrestin 1 and 2 dif-
ferentially regulate TLR4 signaling pathways and, in
particular, b-arrestin 2 negatively regulates the inflam-
matory response in CLP-induced mortality [5,6].
During septic shock, eicosanoids, proinflammatory
cytokines, such as TNF-a, IL-1b, IL-3, IL-6, IL-8, and
antiinflammatory mediators, such as IL-2, IL-4, and IL-
10, are dramatically increased to block the infection and
tissue damage [7-10]. Severe sepsis associated with
hypotension, acute respiratory distress syndrome
(ARDS), hepatic failure, disseminated intravascular coa-
gulation, and organ dysfunction, is characterized by a
poor prognosis; these changes are well documented first
in the lung and then in the liver [11].
In addition, COX-2 and 5-LOX products derived from
arachidonic acid, such as prostaglandins and leuko-
trienes, are responsible for the microvasculature failure,
and are implicated as pathogenic mediators in endotoxe-
mia [12]. Pharmacologic agents that modulate eicosanoid
metabolism have been used to block the inflammatory
response of various diseases, including septic shock
[9,13-15]. Ito and co-workers [14] have shown that mice
pretreated with a 5-LOX inhibitor have a reduced TNF-a
production and attenuated liver injury during endotoxe-
mia. Moreover, early survival improvement was found in
endotoxin-challenged mice, but not in CLP mice, treated
with a selective COX-2 inhibitor [15]. Conversely, it has
been demonstrated that anti-TNF antibody and IL-1
receptor antagonist, as well as COX or LOX pathways
single inhibitors, failed to protect patients with septice-
mia and septic shock. Altogether, these results support
the effort to find a novel strategy; the development of
dual inhibitors of COX-2 and 5-LOX pathways may
represent new insights into the treatment of sepsis,
thanks to the anti-inflammatory efficacy and the lower
incidence of gastric toxicity [16].
Recently, we demonstrated that flavocoxid, which con-
tains both the naturally occurring flavonoids baicalin and
catechin isolated from Scutellaria baicalensis (S. baica-
lensis) and Acacia catechu (A. catechu), respectively, acts
as a dual inhibitor of COX-2 and 5-LOX and blunts the
proinflammatory phenotype in LPS-stimulated macro-
phages [17]; in addition, it holds immunomodulatory and
antiinflammatory activities in experimental models
in vivo, as shown in a murine model of Duchenne mus-
cular dystrophy [18] and in rats subjected to acute caeru-
lein-induced pancreatitis [19].
To date, a dual inhibitor of both COX-2 and 5-LOX
pathways has not been investigated in CLP-induced
lethal sepsis in mice. Therefore, the aim of our study
was to evaluate the potential therapeutic effect of flavo-
coxid, in a murine cecal-ligation puncture model of
polymicrobial sepsis-induced mortality.
Materials and methods
Animals, experimental procedure, and treatments
All procedures complied with the standards for the care
and use of animal subjects, as stated in the Guide for
the Care and Use of Laboratory Animals, and were
approved by the Committee on Animal Health and Care
of Messina University. The 5-week-old male C57BL/6J
mice (Charles River, Calco, LC, Italy), used for this
study, had free access to a standard diet and tap water.
They were maintained on a 12-hour light/dark cycle at
21°C.
Cecal ligation and puncture (CLP) was performed in
C57BL/6J mice as previously described [6]. Specifically,
mice were anesthetized with ether, and a midline inci-
sion was made below the diaphragm to expose the
cecum. The cecum was ligated at the colon juncture
with a 4-0 silk ligature suture without interrupting
intestinal continuity. The cecum was punctured once
with a 22-gauge needle. The cecum was returned to the
abdomen, and the incision was closed in layers with a 4-
0 silk ligature suture. After the procedure, the animals
were fluid-resuscitated with sterile saline (1 ml) injected
subcutaneously (sc). Sham controls were subjected to
the same procedures as were those with CLP without
ligation and puncture of the cecum. Shams were treated
with flavocoxid or vehicle. CLP animals were rando-
mized to receive flavocoxid with and without gentamicin
(3.2 mg/kg, sc), or baicalin (16 mg/kg, ip), or catechin (4
mg/kg, ip), or its vehicle (0.9% NaCl solution). On the
basis of previous data, 20 mg/kg was chosen as the opti-
mal dose of flavocoxid for these experiments [19]. The
doses of baicalin and catechin reflected the ratio (4:1) of
these two molecules in the formulation [17-19]. Flavo-
coxid intraperitoneal (ip) or oral treatment was started 1
hour after the CLP procedure and repeated every 12
hours. The same protocol was used for baicalin and
catechin treatment. In a first experiment, mice were
subjected to CLP (n = 15 per group) or sham operation
(n = 10 per group), and survival was monitored every 24
hours for a total of 120 hours. In a second experiment,
six mice per group were subjected to sham operation or
CLP, and NF-B, MAP kinases, TNF-a, IL-6, IL-10, and
b-arrestin 2 expression was determined in the lung and
liver after 18 hours. In the same animals, a specimen
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from lung and liver was also collected for MPO activity
and histologic analysis, and blood was drawn for mea-
suring serum cytokines, eicosanoids, and lipoxin A4
levels.
Isolation of cytoplasmic and nuclear proteins
In brief, lung and liver samples were homogenized in 1
ml lysis buffer (25 mM Tris/HCl, pH 7.4, 1.0 mM ethy-
lene glycol tetraacetic acid, 1.0 mM ethylenediamine tet-
raacetic acid, 0.5 mM phenylmethyl sulfonylfluoride, 10
μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstatin
A, and 100 mM Na3VO4). The homogenate was sub-
jected to centrifugation at 15,000 g for 15 minutes. The
supernatant was collected and stored at -80°C. The con-
centration of total proteins was determined by using a
Bio-Rad protein-assay kit (Milan, Italy).
Determination of b-arrestin 2, NF-B, TNF-a, p-ERK 1/2, p-
JNK, COX-2, 5-LOX, IL-6, and IL-10 with Western blot
analysis
b-Arrestin 2, NF-B, TNF-a, p-ERK 1/2, p-JNK, COX-2,
5-LOX, IL-6, and IL-10 expression was evaluated with
Western blot, according to the method described pre-
viously [17]. Primary antibodies for NF-B, TNF-a, IL-
6, IL-10, COX-2, 5-LOX, and b-arrestin 2 were pur-
chased from Abcam (Cambridge, UK), whereas primary
antibodies for p-ERK 1/2 and p-JNK were purchased
from Biovision (Mountain View, CA, USA). Secondary
antibodies, peroxidase conjugated, were obtained from
Pierce (Rockford, IL, USA). The protein signals were
quantified by scanning densitometry by using a bio-
image analysis system (Bio-Profil Celbio, Milan, Italy)
and were expressed as integrated intensity in compari-
son with those of control normal animals measured
with the same batch [17].
TNF-a, IL-6, IL-10, and lipoxin A4 production
TNF-a, IL-6, and IL-10 were measured by using
enzyme-linked immunosorbent assay (ELISA) kits
(eBioscience, San Diego, CA, USA). Lipoxin A4 produc-
tion was analyzed with the ELISA kit (Oxford Biomedi-
cal Research, Oxford, MS, USA) and by following the
manufacturer’s instructions.
LTB4 and PGE2 production
Blood was collected, stored at -80°C, and analyzed for
LTB4 by using a commercially available ELISA kit (R&D
Systems, Minneapolis, MN, USA). Samples were run in
duplicate, and the absorbance was read at 450 nm. The
intensity of the color was proportional to the concentra-
tion of LTB4 in the sample. PGE2 production was
assayed without purification by using the Cayman EIA
kit (Cayman, Ann Arbor, MI, USA). Samples were run
in duplicate, and the absorbance was read at 412 nm
and was directly proportional to the content of PGE2 in
samples.
Myeloperoxidase activity
MPO activity was determined in the lung and liver as an
index of neutrophil accumulation, as previously
described [6]. MPO activity of tissue was expressed in
units per 100 mg of tissue.
Histologic evaluation
For light microscopy, lung and liver tissues were rapidly
removed and fixed in 10% buffered formalin. Subse-
quently, they were embedded in paraffin, cut, and
stained with hematoxylin and eosin (H&E). Assessment
of tissue changes was carried out by an experienced
pathologist who was blinded to the treatments. The his-
tologic study of liver sections was based on the follow-
ing parameters: infiltration of inflammatory cells,
steatosis, necrosis, and ballooning degeneration. The
parameters considered for scoring lung damage were
infiltration of inflammatory cells, vascular congestion,
and interstitial edema. All parameters were evaluated by
the following score scale of values: 0, absent; 1, mild; 2,
moderate; and 3, severe.
Drugs
Flavocoxid (Limbrel), baicalin, and catechin were a kind
gift of Primus Pharmaceuticals, Inc. (Scottsdale, AZ,
USA). Gentamicin sulfate was purchased from Sigma
Aldrich (St. Louis, MO, USA). All the compounds were
dissolved in 0.9% NaCl solution.
Statistical analysis
Data are expressed as the mean ± SD. All other data
were analyzed with ANOVA followed by post hoc eva-
luation (Bonferroni test) by using GraphPad Prism Soft-
ware, (San Diego, CA, USA). For the histologic results,
statistical analysis was performed by using the Kruskal-
Wallis test followed by the Mann-Whitney U test. Survi-
val rates were analyzed with the Kaplan-Meier method,
followed by the Log Rank test. A value of P < 0.05 was
selected as the criterion for statistical significance.
Results
Effects of flavocoxid on CLP-induced mortality
For mortality studies, C57BL/6 mice subjected to CLP
or sham operation were treated with flavocoxid (20 mg/
kg/ip) or vehicle, 1 hour after CLP. All the CLP animals
were fluid resuscitated with sterile 0.9% NaCl saline
solution (1 ml/mouse). Flavocoxid treatment was
repeated every 12 hours. Mouse survival was monitored
for up to 120 hours. CLP-induced sepsis in mice pro-
duced severe mortality (P < 0.01) with respect to sham
animals. Flavocoxid treatment did not affect survival in
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sham animals, but significantly reduced mortality (P <
0.01) in CLP mice (Figure 1). Flavocoxid, administered
orally at the same dosage, produced an overlapping
effect on the survival rate (Figure 1). Furthermore, the
combination of flavocoxid with gentamicin (adminis-
tered subcutaneously at the dose of 3.2 mg/day through-
out the experiment) caused a greater improvement in
the survival rate (Figure 1). Neither baicalin (16 mg/kg/
ip) nor catechin (4 mg/kg/ip), administered in the same
percentage as in the 20 mg/kg/ip of flavocoxid, signifi-
cantly modified survival (Figure 1).
Effects of flavocoxid on TNF-a, IL-6, and IL-10 expression
Inflammatory cytokines have a crucial role in CLP-
induced sepsis and mortality. Therefore, we studied the
effects of flavocoxid on CLP-induced TNF-a, IL-6, and
IL-10 expression in lung and liver of mice. Basal protein
levels of TNF-a, IL-6, and IL-10 were measured in lung
(Figure 2a-c) and liver (Figure 2d-f) of sham mice. CLP
mice showed a significant increase in these cytokines (p
< 0.005) compared with sham (Figure 2a-f). Flavocoxid
did not change protein expression in sham animals, but
markedly inhibited the expression of TNF-a and IL-6 in
CLP animals (P < 0.005); moreover, IL-10 protein
expression was further enhanced after treatment in both
lung (Figure 2a-c) and liver (Figure 2d-f) tissues of sep-
tic animals.
Flavocoxid reduces COX-2 and 5-LOX CLP-induced
expression, serum cytokines, LTB4 and PGE2, and
increases lipoxin A4
To verify in vivo the protective effect of flavocoxid, we
first evaluated COX-2 and 5-LOX expression in lung
and liver of both CLP and sham mice. Sham mice
showed a low expression of COX-2 and 5-LOX in both
lung and liver (Figure 3a-d), and no differences were
found between sham animals given either flavocoxid or
vehicle. In contrast, the expression of both enzymes was
increased in lung and liver of CLP mice, with respect to
sham mice. Flavocoxid treatment significantly reduced
Figure 1 Effect of flavocoxid on survival in mice with cecal ligation and puncture (CLP). C57BL/6J mice were subjected to CLP (n = 15 per
group) or sham operation (n = 10 per group). All the CLP animals were fluid resuscitated with sterile NaCl 0.9% saline solution (1 ml/mouse).
Animals were treated with flavocoxid (20 mg/kg, ip) with and without gentamicin (3.2 mg/kg, sc), or baicalin (16 mg/kg, ip), or cathechin (4 mg/
kg, ip), or vehicle (NaCl 0.9%) 1 hour after surgery, repeated every 12 hours. Mouse survival was monitored every 24 hours for a total of 120
hours, and expressed as percentage of mice survived at each time point. *P < 0.01 compared with sham + vehicle or flavocoxid; #P < 0.01
compared with CLP + vehicle; §P < 0.01 compared with CLP + vehicle.
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Figure 2 Western blot analysis of TNF-a, IL-6, and IL-10 in the lung (a through c) and liver (d through f) of CLP and sham mice.
Animals were treated with flavocoxid (20 mg/kg, ip) or vehicle (NaCl 0.9%) 1 hour after surgery, repeated every 12 hours. Bars represent the
mean ± SD of six animals. *P < 0.005 compared with sham + vehicle or flavocoxid; #P < 0.005 compared with CLP + vehicle.
Figure 3 Western blot analysis of COX-2 and 5-LOX in the lung (a and b) and liver (c and d) of CLP and sham mice. Animals were
treated with flavocoxid (20 mg/kg, ip) or vehicle (NaCl 0.9%) 1 hour after surgery, repeated every 12 hours. Bars represent the mean ± SD of six
animals. *P < 0.005 compared with sham + vehicle or flavocoxid; #P < 0.005 compared with CLP + vehicle.
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COX-2 and 5-LOX expression either in lung and in liver
of CLP mice (Figure 3a-d).
Circulating levels of TNF-a, IL-6, and IL-10 were
also measured 18 hours after surgery. Serum cytokines
were significantly augmented in the bloodstream of
CLP mice (Figure 4a-c). Flavocoxid treatment markedly
blunted the serum concentration of TNF-a (Figure 4a)
and IL-6 (Figure 4b), but increased serum IL-10
(Figure 4c).
Serum PGE2 and LTB4 measurements were also deter-
mined in CLP and sham mice, 18 hours after surgery.
Figure 5a and 5b shows a significant increase of both
PGE2 and LTB4 in serum of CLP mice. As a conse-
quence of COX-2 and 5-LOX inhibition by flavocoxid
treatment, PGE2 and LTB4 serum levels were signifi-
cantly reduced in CLP mice (P < 0.005) (Figure 5a and
5b). Lipoxin A4 was also enhanced in the serum of CLP
mice 18 hours after surgery (Figure 5c). Flavocoxid
administration caused a greater increase in the circulat-
ing antiinflammatory lipid mediator, thus suggesting
that this antiinflammatory mechanism may concur with
the protective effect of flavocoxid (Figure 5c).
Flavocoxid regulates CLP-induced expression of NF-B, p-
ERK, p-JNK, and b-arrestin 2
NF-B is a transcription factor that is triggered by TLR
activation and causes the nuclear activation of inflam-
matory genes involved in sepsis. Nuclear NF-B was
markedly expressed in the lung (Figure 6a) and in the
liver (Figure 6c) of CLP mice, 18 hours after surgery.
Flavocoxid treatment blunted the increased nuclear
expression of NF-B in both the lung (Figure 6a) and
the liver (Figure 6c). To determine whether b-arrestin 2
plays a key role in modulating the TLR signaling path-
way in CLP-induced inflammation, b-arrestin 2 protein
expression in lung and liver of sham and CLP mice was
studied. Basal levels of b-arrestin 2 were measured in
lung and liver of sham animals (Figure 6b and 6d). As
shown in Figure 6b and 6d, b-arrestin 2 expression was
significantly reduced in lung and liver of mice subjected
Figure 4 Serum TNF-a (a), IL-6 (b), and IL-10 (c) levels obtained from CLP and sham mice. Animals were treated with flavocoxid (20 mg/
kg, ip or vehicle (NaCl 0.9%) 1 hour after surgery, repeated every 12 hours. Bars represent the mean ± SD of six animals. *P < 0.005 compared
with sham + vehicle or flavocoxid; #P < 0.005 compared with CLP + vehicle.
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to CLP (P < 0.005) compared with sham-operated ani-
mals. Treatment with flavocoxid preserved b-arrestin 2
expression in both lung and liver of CLP mice (Figure
6b and 6d), but it did not affect basal values of b-
arrestin 2 in sham animals.
Furthermore, to better characterize the mechanism of
action of flavocoxid, p-ERK 1/2 and p-JNK were evalu-
ated. A low expression of either p-ERK (Figure 7a and
7c) or p-JNK (Figure 7b and 7d) was determined in
both lung and liver of sham mice. No significant differ-
ences were found in MAPKs expression in sham animals
administered flavocoxid. CLP mice showed a significant
increase in the expression of MAPKs with respect to
sham animals (Figure 7a to 7d). In contrast, flavocoxid
treatment significantly reduced (P < 0.005) p-ERK and
p-JNK expression in lung and liver of CLP animals (Fig-
ure 7a to 7d), suggesting that b-arrestin 2 regulates sep-
sis-induced MAPK activity in vivo.
Effects of flavocoxid on histologic changes and
myeloperoxidase activity
Sham animals treated with either vehicle or flavocoxid
showed a normal architecture of lung and liver (Figure 8a
and 8d; Tables 1 and 2). CLP induced damage in lung and
liver, characterized by microscopic alterations, hemorrha-
gic areas, and marked leukocyte infiltration (Figure 8b and
8e; Tables 1 and 2). In CLP mice, lung histologic examina-
tion showed ample inflammatory infiltrate, interstitial
edema, and marked vascular congestion (Figure 8b and
Table 1). The histologic picture showed that liver damage
was characterized by a high degree of inflammatory infil-
trate, steatosis, necrosis, ballooning degeneration, as well
Figure 5 Serum PGE2 (a), LTB4 (b), and lipoxin A4 (c) levels
obtained from CLP and sham mice. Animals were treated with
flavocoxid (20 mg/kg, ip) or vehicle (NaCl 0.9%) 1 hour after surgery,
repeated every 12 hours. Bars represent the mean ± SD of six
animals. *P < 0.005 compared with sham + vehicle or flavocoxid; #P
< 0.005 compared with CLP + vehicle.
Figure 6 Western blot analysis of NF-B and b-arrestin 2 in lung (a, b) and liver (c, d) of CLP and sham mice. Animals were treated with
flavocoxid (20 mg/kg, ip) or vehicle (NaCl 0.9%) 1 hour after surgery, and repeated every 12 hours. Bars represent the mean ± SD of six animals.
*P < 0.005 compared with sham + vehicle or flavocoxid; #P < 0.005 compared with CLP + vehicle.
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Figure 7 Western blot analysis of p-ERK 1/2 and p-JNK in lung (a, b) and liver (c, d) of CLP and sham mice. Animals were treated with
flavocoxid (20 mg/kg, ip) or vehicle (NaCl 0.9%) 1 hour after surgery, repeated every 12 hours. Bars represent the mean ± SD of six animals. *P <
0.005 compared with sham + vehicle or flavocoxid; #P < 0.005 compared with CLP + vehicle.
Figure 8 Histology of treated and untreated mice. (a) Normal histology of lung obtained from sham mice. (b) Representative cecal ligation
and puncture (CLP)-induced lung damage. (c) Representative lung of CLP mice treated with flavocoxid (20 mg/kg, ip, administered 1 hour after
surgery, repeated every 12 hours). (d) Normal histology of liver obtained from sham mice. (e) Representative CLP-induced liver damage. (f)
Representative liver of CLP mice treated with flavocoxid (20 mg/kg, ip, administered 1 hour after surgery, repeated every 12 hours). Sham and
CLP mice were killed 18 hours after surgery. Histopathology was performed on lung and liver. Original magnification, ×20.
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as morphologic alterations of the nuclei (Figure 8e and
Table 2). In contrast, treatment with flavocoxid signifi-
cantly reduced the histopathologic alterations in the lung
(Figure 8c) and liver (Figure 8f) of CLP mice. Lung histol-
ogy revealed a reduced inflammatory infiltrate, vascular
congestion, and interstitial edema (Figure 8c and Table 1).
After flavocoxid treatment, liver inflammatory infiltrate
and steatosis were less evident, necrosis was absent, and
normal cellular architecture was restored (Figure 8f and
Table 2).
To confirm the antiinflammatory effects of flavocoxid,
we evaluated myeloperoxidase (MPO) activity, a marker
of neutrophil infiltration in both the lung (Figure 9a)
and the liver (Figure 9b) of CLP mice 18 hours after
surgery. MPO content was markedly increased in the
lung (Figure 9a) and in the liver (Figure 9b) of septic
mice. The dual inhibitor of COX-2 and 5-LOX markedly
reduced leukocyte infiltration in the lung (Figure 9a)
and in the liver (Figure 9b) of CLP mice.
Discussion
Flavonoids have been used in traditional remedies for
the treatment of a variety of diseases, including inflam-
matory conditions [20-22]. Flavocoxid, marketed as Lim-
brel, is an FDA-regulated prescription, medical food, for
the clinical dietary management of OA in United States,
which contains the flavonoids, baicalin and catechin
[23].
We previously showed that flavocoxid reduced the
expression of both COX-2 and 5-LOX enzymes and
inhibited the activation of the transcription factor NF-
B in LPS-stimulated macrophages in vitro [17]. There-
fore, we evaluated the effects of flavocoxid in an in vivo
murine model of polymicrobial sepsis, which better
reproduces human sepsis.
Li et al. [9] demonstrated that NS-398, a selective
inhibitor of COX-2, ameliorates cytokine imbalance and
decreases liver injury in septic rats. Additionally, Reddy
et al. [15] showed that treatment with a COX-2 inhibi-
tor improves early survival in murine endotoxemia but
not in CLP mice. Our study demonstrates for the first
time that a dual COX-2 and 5-LOX inhibitor exerts
beneficial effects in a murine CLP model of abdominal
sepsis. In the present study, flavocoxid significantly
improved survival in CLP mice; this protective effect
was strongly associated with reduced expression and
production of proinflammatory cytokines TNF-a and
IL-6, as well as with increased antiinflammatory IL-10
protein level.
Recently, different studies have shown that b-arrestin
2, a member of the arrestin family originally known for
its prominent role in desensitization process of G pro-
tein-coupled receptors, plays an important function in
the signal-transduction pathway of TLR4 [5,24,25]. We
found that b-arrestin 2 expression was significantly
reduced in lung and liver of CLP mice compared with
sham mice, and, in parallel experiments, CLP-induced
TNF-a, IL-6, and IL-10 expression was significantly
higher in control mice. Our findings, therefore, are in
agreement with those of other studies, which indicate b-
arrestin 2 as a negative regulator of the CLP-induced
inflammatory response [5,6,26,27]. It was demonstrated
that b-arrestin 2 downregulates inflammatory responses
in polymorphonuclear leukocytes [26] as well as in sple-
nocytes after CLP induction [6]. An altered cytokine
production was also found by Wang et al. [27] in bone
marrow-derived macrophages from b-arrestin 2-deficient
mice, in response to LPS. All these data suggest that b-
arrestin 2 is an essential negative regulator of sepsis-
induced inflammation via TLR signaling and may repre-
sent an innovative target for antisepsis drugs.
However, conflicting results were obtained by Porter
et al. [28] in regulating inflammatory cytokines produc-
tion in beta arrestins knockout (KO) mice during endo-
toxic shock; the observed differences might be explained
by the use of a different shock model.
Flavocoxid, given curatively, restored b-arrestin 2 to
basal levels and blunted CLP-induced increase in TNF-
Table 1 Flavocoxid effects on lung histologic damage in
CLP mice











0 0 2.12 ±
0.20
1.25 ± 0.27a
Interstitial edema 0 0 2.33 ±
0.41
1.25 ± 0.52a
Histologic grading as reported in Methods; six mice per group treated with
flavocoxid (20 mg/kg, ip).aP < 0.05 versus CLP.
Table 2 Flavocoxid effects on liver histologic damage in CLP mice
Parameter Sham Sham + flavocoxid CLP CLP + flavocoxid
Inflammatory infiltrate 0 0 2.52 ± 0.52 1.55 ± 0.46a
Steatosis 0 0 2.33 ± 0.41 1.47 ± 0.26a
Necrosis 0 0 2.77 ± 0.23 0b
Ballooning degeneration 0 0 2.17 ± 0.26 0.21 ± 0.12b
Histologic grading as reported in Methods; six mice per group treated with flavocoxid (20 mg/kg, ip). aP < 0.05 versus CLP; bP < 0.001 versus CLP.
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a and IL-6, but not IL-10 production in both lung and
liver tissues. In addition, flavocoxid reduced serum levels
of PGE2 and LTB4 as a consequence of a downregula-
tion of COX-2 and 5-LOX expression in lung and liver
of mice subjected to CLP, implicating the same mechan-
ism of action of flavocoxid as reported in our previous
studies [17-19,23]. These findings are further supported
by histologic examinations: flavocoxid treatment
restored organ damage specifically in lung and liver that
are profoundly involved in the pathophysiologic changes
that occur during sepsis. Interestingly, besides acting as
a dual inhibitor of COX-2 and 5-LOX, flavocoxid might
stimulate b-arrestin through some yet-unrecognized
mechanism.
It has been suggested that b-arrestin 2 acts as scaffold
for ERK and JNK cascades, thus leading to modulation of
transcriptional events [24,25]. In our experimental
model, CLP-induced MAPKs expression was significantly
increased in both lung and liver tissues compared with
that in sham mice. Reduced p-ERK1/2 and p-JNK expres-
sion was found after flavocoxid treatment of CLP mice,
thus suggesting that the compound may upregulate b
arrestin 2 through a MAPKs-dependent mechanism.
All these data, taken together, confirm that b-arrestin
2 plays a critical role in a clinically relevant model of
sepsis, as already shown by Fan et al. [6], and support
the hypothesis that b-arrestin 2 improved expression is
protective in a model of abdominal sepsis.
However, additional mechanism(s) underlying flavo-
coxid beneficial effects in experimental sepsis might be
taken into account. NF-B is an early signal that activates
an inflammatory cascade leading to the expression of
cell-adhesion molecules and cytokines and finally culmi-
nating in the deleterious accumulation of leukocytes in
peripheral organs such as lung and liver [29]. Because of
this, CLP animals showed an increased nuclear NF-B
expression and an enhanced content of MPO, a marker
of neutrophil accumulation, in both lung and liver. Flavo-
coxid administration succeeded in reducing these steps
of the inflammatory cascade, thus suggesting that the
dual inhibitor of COX-2 and 5-LOX may work as an NF-
B inhibitor. Furthermore, lipoxin A4, another lipid med-
iator that is endogenously derived from arachidonic acid
metabolism, has been shown to possess marked antiin-
flammatory and pro-resolving effects [30]. Our results
suggest that flavocoxid treatment augmented the levels of
lipoxin A4: therefore, this effect may concur in the overall
protective activity of this natural antiinflammatory drug.
Finally, we established for the first time that a natural
derived dual inhibitor of COX-2 and 5-LOX activity is
able to improve survival and restore the histologic archi-
tecture of lung and liver of mice subjected to polymicro-
bial sepsis. However, further studies will be necessary to
characterize better whether other mediators contribute
in the mechanism of action of flavocoxid in this model
of sepsis.
Conclusions
This is the first report demonstrating that flavocoxid, a
dual COX-2 and 5-LOX inhibitor of natural origin,
Figure 9 Myeloperoxidase (MPO) activity in the lung (a) and liver (b) obtained from CLP and sham mice. Animals were treated with
flavocoxid (20 mg/kg, ip) or vehicle (NaCl 0.9%) 1 hour after surgery, repeated every 12 hours. Bars represent the mean ± SD of six animals. *P <
0.005 compared with sham + vehicle or flavocoxid; #P < 0.005 compared with CLP + vehicle.
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exerts an antiinflammatory response and protects mice
from sepsis in a murine model of CLP. Therefore, on
the basis of efficacy and safety profile [17-19,23,31], fla-
vocoxid represents a novel antiinflammatory therapy
and a potential approach for future clinical trials in
patients with sepsis.
Key messages
• Despite a massive effort invested in developing
potential therapies, to date, severe sepsis is still a
common, frequently fatal, and expensive pathologic
condition.
• Because of the enhanced antiinflammatory efficacy
and the lower incidence of gastric toxicity, the devel-
opment of dual inhibitors of COX-2 and 5-LOX
pathways may represent a new strategy to fight
severe sepsis.
• Flavocoxid, which contains both the naturally
occurring flavonoids baicalin and catechin isolated
from S. baicalensis and A. catechu, respectively, acts
as a dual inhibitor of COX-2 and 5-LOX and blunts
the proinflammatory phenotype in LPS-stimulated
macrophages.
• Cecal ligation and puncture (CLP) is an experi-
mental model of shock that reproduces all the
pathologic sequelae of sepsis that occur in intensive
care patients. b-Arrestin 2 is an essential negative
regulator of sepsis-induced inflammation via TLR
signaling and may represent an innovative target for
antisepsis drugs. Flavocoxid reduced the inflamma-
tory cascade associated with sepsis, enhanced b-
arrestin 2, and improved the survival rate.
• By inhibiting both COX-2 and 5-LOX expression
and stimulating the negative regulator b-arrestin 2
through an MAPKs-dependent mechanism, flavo-
coxid may represent a potential new approach to the
treatment of sepsis.
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